 BiondVax Pharmaceuticals Ltd. Nasdaq: BVXV, developer of the M001 universal influenza vaccine candidate, today announced receipt of proceeds of approximately 4.2 million since January 1, 2020 through exercises of BiondVax warrants. The publicly traded warrants, which were issued to investors in connection with BiondVaxs initial public offering on Nasdaq in 2015, had an exercise price of 6.25, traded on Nasdaq under the symbol BVXVW, and expired May 15, 2020. Warrants issued to underwriters in connection with the initial public offering expired May 11, 2020. 